Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

Share Price is delayed by 15 minutes
Get Live Data
1.80    0.00 (0.00%)
Bid:
1.60
Ask:
2.00
Spread: 0.40 (25.00%)
Market Cap: £7.87m
RENX Live PriceLast checked at - London Stock Exchange

Intraday Renalytix Plc Share Chart

Form 8.5 (EPT/RI) - Renalytix Plc

2 Aug 2024 10:21

Form 8.5 (EPT/RI) - Renalytix Plc

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the β€œCode”)

1. KEY INFORMATION

(a) Name of exempt principal trader:Investec Bank plc
(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeRenalytix Plc
(c) Name of the party to the offer with which exempt principal trader is connected:Investec is Joint Broker to Renalytix Plc
(d) Date dealing undertaken:01st August 2024
(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state β€œN/A”N/A

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchases/ sales Total number of securitiesHighest price per unit paid/receivedLowest price per unit paid/received
Ordinary Shares Purchase 9,480 16 16

(b) Cash-settled derivative transactions

Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
N/AN/AN/AN/AN/A

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit
N/AN/AN/AN/AN/AN/AN/AN/A

(ii) Exercise

Class of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit
N/AN/AN/AN/AN/A

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)
N/AN/AN/AN/A

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state β€œnone”
None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state β€œnone”
None s

Date of disclosure:02nd August 2024
Contact name:Abhishek Gawde
Telephone number:+91 9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
29th May 20264:24 pmRNSHolding(s) in Company
27th May 202611:20 amRNSHolding(s) in Company
18th May 20263:52 pmRNSHolding(s) in Company
5th May 20263:26 pmRNSHolding(s) in Company
5th May 20269:39 amRNSHolding(s) in Company
1st May 20269:23 amRNSHolding(s) in Company
29th Apr 20264:17 pmRNSHolding(s) in Company
23rd Apr 202611:46 amRNSHolding(s) in Company
23rd Apr 202611:42 amRNSHolding(s) in Company
22nd Apr 20267:00 amRNSKey milestones achieved for kidneyintelX.dkd
16th Apr 20266:04 pmRNSHolding(s) in Company
16th Apr 20269:16 amRNSHolding(s) in Company
9th Apr 20264:29 pmRNSHolding(s) in Company
7th Apr 20265:25 pmRNSHolding(s) in Company
7th Apr 20265:24 pmRNSHolding(s) in Company
30th Mar 20263:41 pmRNSHolding(s) in Company
26th Mar 20267:00 amRNSHalf-year Report
18th Mar 20261:55 pmRNSHolding(s) in Company
17th Mar 202611:22 amRNSHolding(s) in Company
13th Mar 20262:02 pmRNSHolding(s) in Company
13th Mar 20262:02 pmRNSHolding(s) in Company
27th Feb 20267:00 amRNSHolding(s) in Company
13th Feb 20262:30 pmRNSFurther CEO Share Purchase
13th Feb 20267:00 amRNSDirector/PDMR Shareholding
12th Feb 20267:01 amRNSDirector/PDMR Share Purchase
12th Feb 20267:00 amRNSCEO Share Purchase
11th Feb 20267:00 amRNSH1 Trading update
21st Jan 20263:20 pmRNSHolding(s) in Company
15th Jan 20264:51 pmRNSHolding(s) in Company
12th Jan 20267:00 amRNSThree kidneyintelX.dkd Clinical Integrations
9th Jan 20262:43 pmRNSHolding(s) in Company
6th Jan 20264:28 pmRNSHolding(s) in Company
24th Dec 202512:56 pmRNSHolding(s) in Company
24th Dec 202512:56 pmRNSHolding(s) in Company
23rd Dec 20254:13 pmRNSHolding(s) in Company
23rd Dec 20254:13 pmRNSHolding(s) in Company
19th Dec 202512:18 pmRNSHolding(s) in Company
19th Dec 202512:18 pmRNSHolding(s) in Company
17th Dec 20251:42 pmRNSHolding(s) in Company
16th Dec 20251:51 pmRNSHolding(s) in Company
9th Dec 202510:57 amRNSResult of AGM
9th Dec 20257:00 amRNSAGM Statement
27th Nov 20252:39 pmRNSHolding(s) in Company
25th Nov 20253:44 pmRNSHolding(s) in Company
25th Nov 20257:00 amRNSPlan to Implement ADS Ratio Change
12th Nov 20257:00 amRNSPivotal kidneyintelX.dkd data published
5th Nov 20254:02 pmRNSHolding(s) in Company
4th Nov 20256:05 pmRNSPublication of Annual Report & Notice of AGM
3rd Nov 202512:05 pmRNSHolding(s) in Company
3rd Nov 20257:00 amRNSAudited Full Year Fiscal 2025 Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.